2023 World Conference on Lung Cancer (Posters)-EP11.03. Site-Specific Response Patterns in Patients with Advanced NSCLC Treated with First-Line Systemic Therapy

EP11.03. Site-Specific Response Patterns in Patients with Advanced NSCLC Treated with First-Line Systemic Therapy - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the site-specific patterns of response and survival in patients with advanced non-small cell lung cancer (NSCLC) who received first-line systemic therapy. The study included 281 patients with unresectable stage III/IV NSCLC without targetable driver mutations who were treated with immunotherapy (IO), chemotherapy (chemo), or the combination of both (chemoIO).<br /><br />The results showed that the overall response rate (ORR) was 40.6%, with the highest response seen in lymph node metastases and lung lesions. On the other hand, bone and liver metastases had the highest rate of site-specific progression. Patients with bone metastases had a shorter progression-free survival (PFS) and overall survival (OS), compared to patients without bone metastases. Similarly, patients with liver metastases had inferior OS.<br /><br />The median OS for patients with bone metastases was 9 months, compared to 21 months for patients without bone metastases. Patients with liver metastases had a median OS of 10 months, compared to 17 months for patients without liver metastases. In patients with bone metastases, treatment with chemoIO improved PFS compared to IO or chemo alone.<br /><br />Disease progression occurred in 80% of patients, with 35% experiencing oligoprogression, most commonly in the primary lung lesion, bone, or brain. Patients with baseline liver metastases were more likely to experience systemic progression of the disease.<br /><br />These findings suggest that NSCLC metastases in different anatomical locations have distinct response patterns. Patients with bone metastases have shorter time to progression and reduced survival outcomes. ChemoIO may be more effective in patients with bone metastases. Additionally, a significant proportion of patients experienced oligoprogressive disease, indicating a potential role for local therapy in this population. Further research is needed to understand the unique mechanisms driving site-specific response and resistance in NSCLC metastases.

Asset Subtitle

Lauren Brown

Meta Tag

Speaker Lauren Brown

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

non-small cell lung cancer

advanced

site-specific patterns

response

survival

systemic therapy

immunotherapy

chemotherapy

metastases

progression-free survival